Quantcast
Study Finds Many Patients Excluded From Clinical Trials Due

Study Finds Many Patients Excluded From Clinical Trials Due To Prior Cancer

UT Southwestern Medical Center Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center. Among more than 50...

Latest lung cancer Stories

2014-09-30 23:01:39

A 2014 study suggests dietary intake of vitamin E may reduce the risk of lung cancer for some women. NutriGold's full-spectrum Vitamin E product is derived from a 100% natural blend of Palm and Sunflower Oil, unlike synthetic Vitamin E supplements. Orem, UT (PRWEB) September 30, 2014 In a 2014 Chinese research study published in the International Journal of Cancer, scientists concluded that dietary intake of Vitamin E may reduce the risk of lung cancer for some women, but that...

2014-09-30 08:30:56

Completion of Enrollment Expected in 2015; Progression-Free Survival Data Expected in mid-2016 LOS ANGELES, Sept. 30, 2014 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy....

2014-09-29 16:26:10

Patient Advocates and Medical Organizations Lay Out Infrastructure and Quality Control Measures WASHINGTON, Sept. 29, 2014 /PRNewswire-USNewswire/ -- More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology and The Society of Thoracic Surgeons, in urging Medicare to cover low dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer. In a new joint letter to...

2014-09-29 12:30:45

BOGOTA, Colombia, Sept. 29, 2014 /PRNewswire/ -- Cancer Treatment Institute of Colombia has announced a promising new drug treatment: a carefully formulated, first-of-its-kind combination of salinomycin and 3-bromopyruvate (3-BrPA) that has already proven successful at treating multiple types of cancer. The team of medical researchers behind this novel treatment are optimistic that it could significantly improve outcomes for many patients who have exhausted current therapeutic...

2014-09-29 08:31:17

Additional Study Focuses on the Detection and Quantitative Monitoring of EGFR Mutations in Lung Cancer Patients SAN DIEGO, Sept. 29, 2014 /PRNewswire/ -- Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that it has expanded its clinical program to include a study designed to evaluate use of the Company's precision cancer monitoring technology in the management of lung cancer patients. The primary objective of the study is to detect and...

2014-09-29 08:30:57

- LUX-Lung 8 trial met its primary endpoint of improving progression-free survival in patients treated with afatinib versus erlotinib after failure of first-line, platinum-based chemotherapy, reducing the risk of disease progression by 18% RIDGEFIELD, Conn., Sept. 29, 2014 /PRNewswire/ -- Phase III data from Boehringer Ingelheim's LUX-Lung 8 trial, the first study to evaluate the superiority of afatinib versus erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung,...

2014-09-27 08:21:15

- AbbVie presents preliminary data from randomized phase 2 trial of veliparib in non-small cell lung cancer NORTH CHICAGO, Ill., Sept. 27, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with...

2014-09-27 04:21:04

LUGANO, Switzerland, September 27, 2014 /PRNewswire/ -- The Helsinn Group, a Company focused on building quality cancer care, announces that anamorelin, its novel, once-daily ghrelin receptor agonist significantly increased lean body mass (LBM) compared with placebo in two Phase III trials comprising the largest trial program of its kind to date in non-small cell lung cancer (NSCLC) patients with cachexia, an area of significant unmet medical need In both pivotal...

2014-09-23 16:27:31

IRVINE, Calif., Sept. 23, 2014 /PRNewswire/ -- Global Discovery Biosciences, a laboratory dedicated to leveraging research and technology to conquer some of the biggest healthcare challenges, announces their collaboration with IPMD, Inc. to develop a simple and highly accurate blood test for the early detection of lung cancer. Lung cancer is the leading cause of cancer death. Typically, the symptoms and subsequent diagnosis of lung cancer appear at an advanced stage of cancer, where the...

2014-09-23 12:27:42

Attendance Doubled and Over $115,000 Raised to Fight Lung Cancer WASHINGTON, Sept. 23, 2014 /PRNewswire-USNewswire/ -- LUNGevity Foundation's Breathe Deep Baltimore walk last Saturday at Oriole Park at Camden Yards was a great success, bringing together 1,020 participants, double the number from last year, and raising over $115,000 for critical lung cancer research, surpassing this year's goal. LUNGevity Foundation was joined by Baltimore residents, the lung cancer community, and...


Latest lung cancer Reference Libraries

Clinical Lung Cancer
2012-05-14 11:09:55

Clinical Lung Cancer is a peer-reviewed medical journal published bimonthly by the CIG Media Group. It was established in 1999. As of May 2012, the editor-in-chief is David R. Gandara. Gandara is a member of the Board of Directors of the International Association for the Study of Lung Cancer and the Addario Foundation. He has also served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and as secretary-treasurer. He is furthermore a member of...

More Articles (1 articles) »
Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related